143 related articles for article (PubMed ID: 9465942)
1. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy.
Pruneri G; Galli S; Rossi RS; Roncalli M; Coggi G; Ferrari A; Simonato A; Siccardi AG; Carboni N; Buffa R
Prostate; 1998 Feb; 34(2):113-20. PubMed ID: 9465942
[TBL] [Abstract][Full Text] [Related]
2. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate.
Schmid KW; Helpap B; Tötsch M; Kirchmair R; Dockhorn-Dworniczak B; Böcker W; Fischer-Colbrie R
Histopathology; 1994 Mar; 24(3):233-9. PubMed ID: 7515371
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A, chromogranin B and secretogranin II mRNAs in the pituitary and adrenal glands of various mammals. Regulation of chromogranin A, chromogranin B and secretogranin II mRNA levels by estrogen.
Lloyd RV; Hawkins K; Jin L; Kulig E; Fields K
Lab Invest; 1992 Sep; 67(3):394-404. PubMed ID: 1405495
[TBL] [Abstract][Full Text] [Related]
6. The prevalence and clinical significance of chromogranin A and secretogranin II immunoreactivity in colorectal adenocarcinomas.
Ferrero S; Buffa R; Pruneri G; Siccardi AG; Pelagi M; Lee AK; Coggi G; Bosari S
Virchows Arch; 1995; 426(6):587-92. PubMed ID: 7655739
[TBL] [Abstract][Full Text] [Related]
7. [Relevance of the neuroendocrine differentiation in prostatic carcinoma].
Sauer CG; Trojan L; Grobholz R
Pathologe; 2005 Nov; 26(6):444-52. PubMed ID: 16133158
[TBL] [Abstract][Full Text] [Related]
8. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
Roudier MP; True LD; Vessella RL; Higano CS
J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
10. [Role of neuroendocrine cells in prostate cancer progression].
Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
Urologia; 2011; 78(2):126-31. PubMed ID: 21574145
[TBL] [Abstract][Full Text] [Related]
11. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2004 Dec; 4(1):14. PubMed ID: 15588310
[TBL] [Abstract][Full Text] [Related]
12. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
13. Immunolocalization of secretogranin II, chromogranin A, and chromogranin B in differentiating human neuroblastoma cells.
Giudici AM; Sher E; Pelagi M; Clementi F; Zanini A
Eur J Cell Biol; 1992 Aug; 58(2):383-9. PubMed ID: 1425774
[TBL] [Abstract][Full Text] [Related]
14. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
[TBL] [Abstract][Full Text] [Related]
15. Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II.
Portela-Gomes GM; Grimelius L; Stridsberg M
Regul Pept; 2010 Nov; 165(1):30-5. PubMed ID: 20550951
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
18. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
19. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity.
Strid H; Simrén M; Lasson A; Isaksson S; Stridsberg M; Öhman L
J Crohns Colitis; 2013 Dec; 7(12):e615-22. PubMed ID: 23694857
[TBL] [Abstract][Full Text] [Related]
20. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
Bollito E; Berruti A; Bellina M; Mosca A; Leonardo E; Tarabuzzi R; Cappia S; Ari MM; Tampellini M; Fontana D; Gubetta L; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S159-64. PubMed ID: 11762345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
